Furthermore, WEE1 targeting was shown to be more efficient in KRAS-mutant NSCLC expressing mutated TP53 [108], indicating that the G2 checkpoint is the major target of WEE1 inhibitors. The gene discussed is TP53; the disease is non-small cell lung carcinoma.